25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ADPT (Adaptive Biotechnologies Corp) Stock Analysis
Buy, Hold or Sell?

Let's analyze Adaptive Biotechnologies Corp together

I guess you are interested in Adaptive Biotechnologies Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Adaptive Biotechnologies Corp’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Adaptive Biotechnologies Corp’s Price Targets

I'm going to help you getting a better view of Adaptive Biotechnologies Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Adaptive Biotechnologies Corp

I send you an email if I find something interesting about Adaptive Biotechnologies Corp.

1. Quick Overview

1.1. Quick analysis of Adaptive Biotechnologies Corp (30 sec.)










1.2. What can you expect buying and holding a share of Adaptive Biotechnologies Corp? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.18
Expected worth in 1 year
$0.77
How sure are you?
10.0%

+ What do you gain per year?

Total Gains per Share
$-0.41
Return On Investment
-3.1%

For what price can you sell your share?

Current Price per Share
$13.08
Expected price per share
$9.9551 - $
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Adaptive Biotechnologies Corp (5 min.)




Live pricePrice per Share (EOD)
$13.08
Intrinsic Value Per Share
$5.60 - $7.13
Total Value Per Share
$6.78 - $8.31

2.2. Growth of Adaptive Biotechnologies Corp (5 min.)




Is Adaptive Biotechnologies Corp growing?

Current yearPrevious yearGrowGrow %
How rich?$179.5m$296.5m-$97.5m-49.0%

How much money is Adaptive Biotechnologies Corp making?

Current yearPrevious yearGrowGrow %
Making money-$30.3m-$53.3m$23m76.1%
Net Profit Margin-60.1%-126.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Adaptive Biotechnologies Corp (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#251 / 853

Most Revenue
#144 / 853

Most Profit
#687 / 853

Most Efficient
#409 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Adaptive Biotechnologies Corp?

Welcome investor! Adaptive Biotechnologies Corp's management wants to use your money to grow the business. In return you get a share of Adaptive Biotechnologies Corp.

First you should know what it really means to hold a share of Adaptive Biotechnologies Corp. And how you can make/lose money.

Speculation

The Price per Share of Adaptive Biotechnologies Corp is $13.08. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Adaptive Biotechnologies Corp.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Adaptive Biotechnologies Corp, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.18. Based on the TTM, the Book Value Change Per Share is $-0.10 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Adaptive Biotechnologies Corp.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.17-1.3%-0.20-1.5%-0.35-2.7%-0.29-2.2%-0.31-2.3%-0.25-1.9%
Usd Book Value Change Per Share-0.07-0.5%-0.10-0.8%-0.25-1.9%-0.19-1.4%-0.12-0.9%0.040.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.07-0.5%-0.10-0.8%-0.25-1.9%-0.19-1.4%-0.12-0.9%0.040.3%
Usd Price Per Share11.65-7.55-4.30-6.47-17.53-17.86-
Price to Earnings Ratio-17.31--9.91--3.09--6.37--15.07--21.40-
Price-to-Total Gains Ratio-166.03--86.31--17.32--47.43--82.72--101.03-
Price to Book Ratio9.88-5.96-2.19-3.59-5.17-3.84-
Price-to-Total Gains Ratio-166.03--86.31--17.32--47.43--82.72--101.03-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share13.08
Number of shares76
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.10-0.12
Usd Total Gains Per Share-0.10-0.12
Gains per Quarter (76 shares)-7.72-8.74
Gains per Year (76 shares)-30.89-34.98
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-31-410-35-45
20-62-720-70-80
30-93-1030-105-115
40-124-1340-140-150
50-154-1650-175-185
60-185-1960-210-220
70-216-2270-245-255
80-247-2580-280-290
90-278-2890-315-325
100-309-3200-350-360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.030.00.00.0%0.030.00.00.0%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%3.024.03.010.0%3.024.03.010.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.030.00.0%0.00.030.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%3.024.03.010.0%3.024.03.010.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Adaptive Biotechnologies Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.070-0.102+45%-0.254+262%-0.185+164%-0.115+64%0.039-279%
Book Value Per Share--1.1791.307-10%1.947-39%2.054-43%2.961-60%2.408-51%
Current Ratio--2.8423.044-7%4.456-36%4.259-33%4.717-40%4.846-41%
Debt To Asset Ratio--0.6380.623+3%0.544+17%0.543+18%0.460+39%0.482+32%
Debt To Equity Ratio--1.7641.652+7%1.202+47%1.239+42%0.946+87%0.747+136%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--1654764100.0001036319607.500+60%634113080.000+161%969569662.500+71%2745413127.500-40%3344549290.800-51%
Eps---0.168-0.199+18%-0.350+108%-0.288+71%-0.305+81%-0.250+49%
Ev To Ebitda Ratio---22.802-11.467-50%-3.638-84%-7.767-66%-17.095-25%-27.326+20%
Ev To Sales Ratio--7.0264.931+42%3.800+85%5.151+36%19.096-63%28.029-75%
Free Cash Flow Per Share---0.086-0.136+58%-0.224+161%-0.213+148%-0.284+230%-0.170+98%
Free Cash Flow To Equity Per Share---0.075-0.124+65%-0.224+197%-0.139+84%-0.136+80%0.002-4779%
Gross Profit Margin--1.9201.743+10%1.408+36%1.578+22%1.524+26%1.526+26%
Intrinsic Value_10Y_max--7.127----------
Intrinsic Value_10Y_min--5.604----------
Intrinsic Value_1Y_max---0.626----------
Intrinsic Value_1Y_min---0.616----------
Intrinsic Value_3Y_max---0.860----------
Intrinsic Value_3Y_min---0.841----------
Intrinsic Value_5Y_max--0.138----------
Intrinsic Value_5Y_min--0.040----------
Market Cap1991743920.000+11%1773992100.0001149478357.500+54%654016830.000+171%985656912.500+80%2669172877.500-34%2719892809.000-35%
Net Profit Margin---0.435-0.601+38%-1.262+190%-0.946+117%-1.120+158%-1.089+150%
Operating Margin---0.385-0.571+49%-1.189+209%-0.916+138%-1.112+189%-1.115+190%
Operating Ratio--1.4251.601-11%2.105-32%1.915-26%2.105-32%2.113-33%
Pb Ratio11.094+11%9.8815.956+66%2.194+350%3.590+175%5.169+91%3.837+158%
Pe Ratio-19.440-12%-17.315-9.910-43%-3.091-82%-6.367-63%-15.073-13%-21.399+24%
Price Per Share13.080+11%11.6507.549+54%4.295+171%6.473+80%17.529-34%17.862-35%
Price To Free Cash Flow Ratio-38.054-12%-33.894-17.167-49%-5.277-84%-9.930-71%-15.041-56%-18.860-44%
Price To Total Gains Ratio-186.406-12%-166.026-86.307-48%-17.320-90%-47.426-71%-82.718-50%-101.030-39%
Quick Ratio--4.3074.672-8%7.087-39%6.717-36%7.405-42%7.725-44%
Return On Assets---0.052-0.057+11%-0.083+60%-0.065+25%-0.060+16%-0.047-9%
Return On Equity---0.143-0.152+7%-0.182+28%-0.145+2%-0.119-17%-0.091-36%
Total Gains Per Share---0.070-0.102+45%-0.254+262%-0.185+164%-0.115+64%0.039-279%
Usd Book Value--179536000.000198954000.000-10%296527750.000-39%312813166.667-43%450915700.000-60%366746400.000-51%
Usd Book Value Change Per Share---0.070-0.102+45%-0.254+262%-0.185+164%-0.115+64%0.039-279%
Usd Book Value Per Share--1.1791.307-10%1.947-39%2.054-43%2.961-60%2.408-51%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--1654764100.0001036319607.500+60%634113080.000+161%969569662.500+71%2745413127.500-40%3344549290.800-51%
Usd Eps---0.168-0.199+18%-0.350+108%-0.288+71%-0.305+81%-0.250+49%
Usd Free Cash Flow---13085000.000-20702000.000+58%-34147000.000+161%-32427166.667+148%-43203450.000+230%-25878366.667+98%
Usd Free Cash Flow Per Share---0.086-0.136+58%-0.224+161%-0.213+148%-0.284+230%-0.170+98%
Usd Free Cash Flow To Equity Per Share---0.075-0.124+65%-0.224+197%-0.139+84%-0.136+80%0.002-4779%
Usd Market Cap1991743920.000+11%1773992100.0001149478357.500+54%654016830.000+171%985656912.500+80%2669172877.500-34%2719892809.000-35%
Usd Price Per Share13.080+11%11.6507.549+54%4.295+171%6.473+80%17.529-34%17.862-35%
Usd Profit---25614000.000-30307250.000+18%-53367500.000+108%-42500916.667+66%-45641350.000+78%-36427266.667+42%
Usd Revenue--58879000.00051304000.000+15%42191500.000+40%46965250.000+25%42834550.000+37%34644100.000+70%
Usd Total Gains Per Share---0.070-0.102+45%-0.254+262%-0.185+164%-0.115+64%0.039-279%
 EOD+5 -3MRQTTM+27 -11YOY+27 -113Y+27 -115Y+21 -1710Y+14 -24

3.3 Fundamental Score

Let's check the fundamental score of Adaptive Biotechnologies Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-19.440
Price to Book Ratio (EOD)Between0-111.094
Net Profit Margin (MRQ)Greater than0-0.435
Operating Margin (MRQ)Greater than0-0.385
Quick Ratio (MRQ)Greater than14.307
Current Ratio (MRQ)Greater than12.842
Debt to Asset Ratio (MRQ)Less than10.638
Debt to Equity Ratio (MRQ)Less than11.764
Return on Equity (MRQ)Greater than0.15-0.143
Return on Assets (MRQ)Greater than0.05-0.052
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Adaptive Biotechnologies Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.898
Ma 20Greater thanMa 5012.807
Ma 50Greater thanMa 10011.941
Ma 100Greater thanMa 20010.807
OpenGreater thanClose12.620
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Fundamental data was last updated by Penke on 2025-08-23 09:27:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Adaptive Biotechnologies Corp earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Adaptive Biotechnologies Corp to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -43.5%Β means thatΒ $-0.44 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Adaptive Biotechnologies Corp:

  • The MRQ is -43.5%. The company is making a huge loss. -2
  • The TTM is -60.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-43.5%TTM-60.1%+16.6%
TTM-60.1%YOY-126.2%+66.1%
TTM-60.1%5Y-112.0%+51.9%
5Y-112.0%10Y-108.9%-3.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-43.5%-85.5%+42.0%
TTM-60.1%-168.0%+107.9%
YOY-126.2%-210.0%+83.8%
3Y-94.6%-289.9%+195.3%
5Y-112.0%-382.7%+270.7%
10Y-108.9%-520.3%+411.4%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Adaptive Biotechnologies Corp is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Adaptive Biotechnologies Corp to theΒ Biotechnology industry mean.
  • -5.2% Return on Assets means thatΒ Adaptive Biotechnologies Corp generatedΒ $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Adaptive Biotechnologies Corp:

  • The MRQ is -5.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.2%TTM-5.7%+0.6%
TTM-5.7%YOY-8.3%+2.5%
TTM-5.7%5Y-6.0%+0.2%
5Y-6.0%10Y-4.7%-1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.2%-11.9%+6.7%
TTM-5.7%-12.0%+6.3%
YOY-8.3%-11.3%+3.0%
3Y-6.5%-12.0%+5.5%
5Y-6.0%-11.7%+5.7%
10Y-4.7%-13.8%+9.1%
4.3.1.3. Return on Equity

Shows how efficient Adaptive Biotechnologies Corp is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Adaptive Biotechnologies Corp to theΒ Biotechnology industry mean.
  • -14.3% Return on Equity means Adaptive Biotechnologies Corp generated $-0.14Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Adaptive Biotechnologies Corp:

  • The MRQ is -14.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -15.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.3%TTM-15.2%+1.0%
TTM-15.2%YOY-18.2%+3.0%
TTM-15.2%5Y-11.9%-3.3%
5Y-11.9%10Y-9.1%-2.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.3%-14.2%-0.1%
TTM-15.2%-15.1%-0.1%
YOY-18.2%-15.1%-3.1%
3Y-14.5%-16.9%+2.4%
5Y-11.9%-17.5%+5.6%
10Y-9.1%-19.7%+10.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Adaptive Biotechnologies Corp.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Adaptive Biotechnologies Corp is operatingΒ .

  • Measures how much profit Adaptive Biotechnologies Corp makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Adaptive Biotechnologies Corp to theΒ Biotechnology industry mean.
  • An Operating Margin of -38.5%Β means the company generated $-0.38 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Adaptive Biotechnologies Corp:

  • The MRQ is -38.5%. The company is operating very inefficient. -2
  • The TTM is -57.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-38.5%TTM-57.1%+18.7%
TTM-57.1%YOY-118.9%+61.7%
TTM-57.1%5Y-111.2%+54.0%
5Y-111.2%10Y-111.5%+0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-38.5%-154.1%+115.6%
TTM-57.1%-270.5%+213.4%
YOY-118.9%-254.3%+135.4%
3Y-91.6%-276.4%+184.8%
5Y-111.2%-350.8%+239.6%
10Y-111.5%-532.3%+420.8%
4.3.2.2. Operating Ratio

Measures how efficient Adaptive Biotechnologies Corp is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 1.43 means that the operating costs are $1.43 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 1.425. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.601. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.425TTM1.601-0.176
TTM1.601YOY2.105-0.503
TTM1.6015Y2.105-0.504
5Y2.10510Y2.113-0.007
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4251.891-0.466
TTM1.6012.917-1.316
YOY2.1053.080-0.975
3Y1.9153.835-1.920
5Y2.1054.924-2.819
10Y2.1136.864-4.751
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Adaptive Biotechnologies Corp.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Adaptive Biotechnologies Corp is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 2.84Β means the company has $2.84 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 2.842. The company is able to pay all its short-term debts. +1
  • The TTM is 3.044. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.842TTM3.044-0.202
TTM3.044YOY4.456-1.412
TTM3.0445Y4.717-1.673
5Y4.71710Y4.846-0.129
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8423.480-0.638
TTM3.0443.795-0.751
YOY4.4564.104+0.352
3Y4.2594.607-0.348
5Y4.7175.762-1.045
10Y4.8466.164-1.318
4.4.3.2. Quick Ratio

Measures if Adaptive Biotechnologies Corp is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Adaptive Biotechnologies Corp to theΒ Biotechnology industry mean.
  • A Quick Ratio of 4.31Β means the company can pay off $4.31 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 4.307. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.672. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.307TTM4.672-0.365
TTM4.672YOY7.087-2.415
TTM4.6725Y7.405-2.732
5Y7.40510Y7.725-0.321
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.3072.952+1.355
TTM4.6723.302+1.370
YOY7.0873.927+3.160
3Y6.7174.393+2.324
5Y7.4055.875+1.530
10Y7.7256.549+1.176
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Adaptive Biotechnologies Corp.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Adaptive Biotechnologies CorpΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Adaptive Biotechnologies Corp to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.64Β means that Adaptive Biotechnologies Corp assets areΒ financed with 63.8% credit (debt) and the remaining percentage (100% - 63.8%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 0.638. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.623. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.638TTM0.623+0.016
TTM0.623YOY0.544+0.079
TTM0.6235Y0.460+0.163
5Y0.46010Y0.482-0.022
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6380.340+0.298
TTM0.6230.355+0.268
YOY0.5440.335+0.209
3Y0.5430.341+0.202
5Y0.4600.349+0.111
10Y0.4820.379+0.103
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Adaptive Biotechnologies Corp is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Adaptive Biotechnologies Corp to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 176.4% means that company has $1.76 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 1.764. The company is just able to pay all its debts with equity.
  • The TTM is 1.652. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.764TTM1.652+0.113
TTM1.652YOY1.202+0.450
TTM1.6525Y0.946+0.706
5Y0.94610Y0.747+0.199
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7640.393+1.371
TTM1.6520.436+1.216
YOY1.2020.436+0.766
3Y1.2390.461+0.778
5Y0.9460.459+0.487
10Y0.7470.514+0.233
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Adaptive Biotechnologies Corp generates.

  • Above 15 is considered overpriced butΒ always compareΒ Adaptive Biotechnologies Corp to theΒ Biotechnology industry mean.
  • A PE ratio of -17.31 means the investor is paying $-17.31Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Adaptive Biotechnologies Corp:

  • The EOD is -19.440. Based on the earnings, the company is expensive. -2
  • The MRQ is -17.315. Based on the earnings, the company is expensive. -2
  • The TTM is -9.910. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-19.440MRQ-17.315-2.125
MRQ-17.315TTM-9.910-7.404
TTM-9.910YOY-3.091-6.819
TTM-9.9105Y-15.073+5.163
5Y-15.07310Y-21.399+6.326
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-19.440-2.537-16.903
MRQ-17.315-2.362-14.953
TTM-9.910-2.678-7.232
YOY-3.091-3.833+0.742
3Y-6.367-3.900-2.467
5Y-15.073-6.480-8.593
10Y-21.399-7.170-14.229
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Adaptive Biotechnologies Corp:

  • The EOD is -38.054. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -33.894. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -17.167. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-38.054MRQ-33.894-4.160
MRQ-33.894TTM-17.167-16.726
TTM-17.167YOY-5.277-11.890
TTM-17.1675Y-15.041-2.127
5Y-15.04110Y-18.860+3.819
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-38.054-3.385-34.669
MRQ-33.894-3.040-30.854
TTM-17.167-3.676-13.491
YOY-5.277-4.421-0.856
3Y-9.930-5.258-4.672
5Y-15.041-8.587-6.454
10Y-18.860-9.639-9.221
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Adaptive Biotechnologies Corp is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 9.88 means the investor is paying $9.88Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Adaptive Biotechnologies Corp:

  • The EOD is 11.094. Based on the equity, the company is expensive. -2
  • The MRQ is 9.881. Based on the equity, the company is overpriced. -1
  • The TTM is 5.956. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD11.094MRQ9.881+1.213
MRQ9.881TTM5.956+3.925
TTM5.956YOY2.194+3.762
TTM5.9565Y5.169+0.787
5Y5.16910Y3.837+1.333
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD11.0942.199+8.895
MRQ9.8811.995+7.886
TTM5.9562.190+3.766
YOY2.1942.415-0.221
3Y3.5902.574+1.016
5Y5.1693.805+1.364
10Y3.8374.462-0.625
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Adaptive Biotechnologies Corp.

4.8.1. Institutions holding Adaptive Biotechnologies Corp

Institutions are holding 98.74% of the shares of Adaptive Biotechnologies Corp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Viking Global Investors LP19.69720.7082999370800
2025-03-31Rubric Capital Management LP8.61461.746613117851-1482149-10.1517
2025-03-31BlackRock Inc8.03140.0019122297931089470.8988
2025-06-30Vanguard Group Inc7.40720.0021112791951357671.2184
2025-03-31Ameriprise Financial Inc4.36220.013366424765905756801.6283
2025-03-31Nikko Asset Management Americas Inc3.99650.58216085690-747447-10.9386
2025-06-30Sumitomo Mitsui Trust Group Inc2.82370.03124299684-1786006-29.3476
2025-06-30ARK Investment Management LLC2.63770.34314016485-3716085-48.0576
2025-03-31ING Investment Management LLC2.63460.01664011880158317065.1856
2025-06-30BRAIDWELL LP2.53691.53923863107-940687-19.5822
2025-03-31Millennium Management LLC1.9670.01192995301-3297333-52.3999
2025-03-31Aristotle Atlantic Partners, LLC1.93150.73742941212545101.8883
2025-03-31Geode Capital Management, LLC1.82620.00162780824963183.5879
2025-03-31State Street Corp1.76630.00082689543-40358-1.4784
2025-03-31Driehaus Capital Management LLC1.41350.154221523351306164154.3617
2025-06-30Blue Water Life Science Advisors, LLC1.408719.7819214514500
2025-06-30Goldman Sachs Group Inc1.26580.00311927443-78001-3.8895
2025-03-31Victory Capital Management Inc.1.15860.0134176422717465719892.2236
2025-06-30Iron Triangle Partners LP0.98242.67621495883-638178-29.9044
2025-03-31Bank of America Corp0.96640.000914715531230557510.613
Total 77.428428.3655117903335-558484-0.5%

4.9.2. Funds holding Adaptive Biotechnologies Corp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31ARK Genomic Revolution5.00395.89647619608-1677986-18.0475
2025-06-30Vanguard Total Stock Mkt Idx Inv2.94820.0027448940310600.0236
2025-07-31ARK Genomic Revolution ETF2.37373.7013614554-21675-0.5961
2025-06-30Nikko AM ARK Pstv Chg Innovt P JPY Acc2.33491.87233555519-116303-3.1674
2025-07-31iShares Russell 2000 ETF2.32070.05973533800-67200-1.8661
2025-03-31Columbia Large Cap Growth SMA Cmp2.13550.4577325177732517770
2025-06-30Columbia Small Cap Growth1.31030.9871995269-250745-11.164
2025-06-30Columbia Small Cap Growth Inst1.31030.9871199526900
2025-06-30Vanguard Institutional Extnd Mkt Idx Tr1.16370.018177200963920.362
2025-06-30Vanguard Small Cap Index1.15740.01321762448-12589-0.7092
2025-05-31Alger Small Cap Focus I1.07151.7775163159037200329.5337
2025-05-31Alger Small Cap Focus Composite1.07151.7775163159037200329.5337
2025-06-30Aristotle Atlantic Focus Growth Equity1.06041.5893161470000
2025-07-31iShares Russell 2000 Growth ETF0.86290.1151131397200
2025-05-31Fidelity Small Cap Index0.77060.0449117345717880.1526
2025-06-30Vanguard Small Cap Growth Index Inv0.65440.0307996454187031.9129
2025-06-30MFS New Discovery I0.63530.539296743500
2025-07-31iShares Biotechnology ETF0.58680.168389358876370.862
2025-06-30Nuveen Quant Small Cap Equity R60.58350.3073888490-17730-1.9565
2025-06-30BNP Paribas Health Cr Innovtr Cl Cap0.54710.534783310425173043.2991
Total 29.902620.879645534036+2118865+4.7%

5.3. Insider Transactions

Insiders are holding 2.343% of the shares of Adaptive Biotechnologies Corp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-05-16Kyle PiskelSELL19298.89
2025-05-01Harlan S RobinsSELL684127.35
2025-03-24Harlan S RobinsSELL16989
2025-03-12Robert HershbergSELL530007.59
2025-03-10Peter M NeupertSELL100007.05
2025-03-06Michelle Renee GriffinSELL156647.94
2025-03-05Chad M RobinsSELL1173516.98
2025-03-05Francis LoSELL208756.99
2025-03-05Julie RubinsteinSELL595056.98
2025-03-05Kyle PiskelSELL103206.98
2025-02-20Chad M RobinsSELL991078.44
2025-02-18Chad M RobinsSELL2111608.5
2025-02-14Chad M RobinsSELL1589218.46
2024-11-18Kyle PiskelSELL2484.98
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets496,637
Total Liabilities317,101
Total Stockholder Equity179,717
 As reported
Total Liabilities 317,101
Total Stockholder Equity+ 179,717
Total Assets = 496,637

Assets

Total Assets496,637
Total Current Assets261,856
Long-term Assets234,781
Total Current Assets
Cash And Cash Equivalents 43,163
Short-term Investments 154,710
Net Receivables 44,285
Inventory 8,403
Other Current Assets 11,295
Total Current Assets  (as reported)261,856
Total Current Assets  (calculated)261,856
+/-0
Long-term Assets
Property Plant Equipment 84,393
Goodwill 118,972
Long Term Investments 24,100
Intangible Assets 2,583
Long-term Assets Other 4,733
Long-term Assets  (as reported)234,781
Long-term Assets  (calculated)234,781
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities92,141
Long-term Liabilities224,960
Total Stockholder Equity179,717
Total Current Liabilities
Short-term Debt 9,957
Accounts payable 6,908
Other Current Liabilities 19,975
Total Current Liabilities  (as reported)92,141
Total Current Liabilities  (calculated)36,840
+/- 55,301
Long-term Liabilities
Capital Lease Obligations 84,370
Long-term Liabilities Other 130,515
Long-term Liabilities  (as reported)224,960
Long-term Liabilities  (calculated)214,885
+/- 10,075
Total Stockholder Equity
Common Stock15
Retained Earnings -1,359,290
Accumulated Other Comprehensive Income 73
Other Stockholders Equity 1,538,919
Total Stockholder Equity (as reported)179,717
Total Stockholder Equity (calculated)179,717
+/-0
Other
Capital Stock15
Cash and Short Term Investments 197,873
Common Stock Shares Outstanding 152,082
Current Deferred Revenue55,301
Liabilities and Stockholders Equity 496,637
Net Debt 41,207
Net Invested Capital 179,717
Net Working Capital 169,715
Property Plant and Equipment Gross 84,393
Short Long Term Debt Total 84,370



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
332,688
614,584
601,395
917,392
912,302
874,886
854,822
1,095,473
1,116,414
1,072,093
1,033,374
992,607
923,344
858,193
806,633
884,208
856,617
791,463
764,540
717,682
661,134
620,323
584,872
558,506
539,376
510,852
496,637
496,637510,852539,376558,506584,872620,323661,134717,682764,540791,463856,617884,208806,633858,193923,344992,6071,033,3741,072,0931,116,4141,095,473854,822874,886912,302917,392601,395614,584332,688000
   > Total Current Assets 
192,150
0
0
180,718
459,148
442,301
601,356
612,690
584,646
599,521
877,358
726,914
764,960
643,729
467,027
402,748
419,120
438,575
564,380
562,146
501,333
476,809
435,237
410,188
374,034
351,552
308,345
283,752
256,489
261,856
261,856256,489283,752308,345351,552374,034410,188435,237476,809501,333562,146564,380438,575419,120402,748467,027643,729764,960726,914877,358599,521584,646612,690601,356442,301459,148180,71800192,150
       Cash And Cash Equivalents 
-192,150
0
0
55,030
111,290
48,458
74,941
96,576
212,688
365,440
497,076
123,436
173,624
184,186
122,401
139,065
114,805
76,412
217,552
90,030
94,612
109,240
88,713
65,064
71,233
59,824
38,084
47,920
50,646
43,163
43,16350,64647,92038,08459,82471,23365,06488,713109,24094,61290,030217,55276,412114,805139,065122,401184,186173,624123,436497,076365,440212,68896,57674,94148,458111,29055,03000-192,150
       Short-term Investments 
384,300
0
0
109,988
329,150
374,543
498,487
480,290
342,485
204,940
338,004
564,833
540,640
414,227
292,639
213,996
248,757
307,326
290,527
408,166
346,083
307,990
282,419
281,337
237,639
232,056
205,245
174,374
142,778
154,710
154,710142,778174,374205,245232,056237,639281,337282,419307,990346,083408,166290,527307,326248,757213,996292,639414,227540,640564,833338,004204,940342,485480,290498,487374,543329,150109,98800384,300
       Net Receivables 
0
0
0
4,807
4,066
7,252
9,257
12,676
9,382
7,914
11,858
10,047
19,754
14,174
17,122
17,409
22,518
23,712
26,549
40,057
30,972
31,545
31,211
37,969
42,021
35,610
40,814
41,731
43,583
44,285
44,28543,58341,73140,81435,61042,02137,96931,21131,54530,97240,05726,54923,71222,51817,40917,12214,17419,75410,04711,8587,9149,38212,6769,2577,2524,0664,807000
       Other Current Assets 
0
0
0
3,055
6,787
8,088
20,008
25,458
9,573
10,691
35,168
14,535
13,520
12,530
16,634
13,015
12,038
12,347
12,407
9,440
9,792
9,074
13,404
21,740
9,850
20,496
12,247
11,287
10,798
11,295
11,29510,79811,28712,24720,4969,85021,74013,4049,0749,7929,44012,40712,34712,03813,01516,63412,53013,52014,53535,16810,6919,57325,45820,0088,0886,7873,055000
   > Long-term Assets 
-192,150
0
0
151,970
155,436
159,094
316,036
299,612
290,240
255,301
218,115
389,500
307,133
389,645
525,580
520,596
439,073
368,058
319,828
294,471
290,130
287,731
282,445
250,946
246,289
233,320
250,161
255,624
254,363
234,781
234,781254,363255,624250,161233,320246,289250,946282,445287,731290,130294,471319,828368,058439,073520,596525,580389,645307,133389,500218,115255,301290,240299,612316,036159,094155,436151,97000-192,150
       Property Plant Equipment 
0
0
0
19,125
21,184
22,298
46,542
60,355
56,010
64,452
68,889
139,042
144,812
167,302
177,266
172,940
171,628
171,250
169,267
164,210
160,254
156,499
152,012
120,323
116,259
103,939
97,844
94,383
88,434
84,393
84,39388,43494,38397,844103,939116,259120,323152,012156,499160,254164,210169,267171,250171,628172,940177,266167,302144,812139,04268,88964,45256,01060,35546,54222,29821,18419,125000
       Goodwill 
0
0
0
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972000
       Long Term Investments 
0
0
0
0
0
0
135,306
105,435
100,618
57,383
16,466
118,525
30,688
91,131
217,379
217,145
137,110
66,928
19,698
0
0
0
0
0
0
0
23,866
33,660
39,355
24,100
24,10039,35533,66023,866000000019,69866,928137,110217,145217,37991,13130,688118,52516,46657,383100,618105,435135,306000000
       Intangible Assets 
0
0
0
13,626
13,207
12,784
12,356
11,928
11,504
11,081
10,653
10,225
9,806
9,383
8,955
8,526
8,107
7,684
7,256
6,827
6,408
5,985
5,557
5,128
4,705
4,281
3,853
3,425
3,006
2,583
2,5833,0063,4253,8534,2814,7055,1285,5575,9856,4086,8277,2567,6848,1078,5268,9559,3839,80610,22510,65311,08111,50411,92812,35612,78413,20713,626000
       Long-term Assets Other 
-192,150
0
0
247
2,073
5,040
2,860
2,922
3,136
3,413
3,135
2,736
2,855
2,857
3,008
3,013
3,256
3,224
4,635
4,462
4,496
6,275
5,904
-1,537
6,353
3,152
5,626
5,184
4,596
4,733
4,7334,5965,1845,6263,1526,353-1,5375,9046,2754,4964,4624,6353,2243,2563,0133,0082,8572,8552,7363,1353,4133,1362,9222,8605,0402,07324700-192,150
> Total Liabilities 
0
0
0
590,800
326,486
885,769
331,467
341,263
323,323
324,883
320,426
373,148
346,376
340,064
341,064
319,242
304,938
288,317
396,394
392,519
367,511
368,573
356,045
352,856
345,557
343,442
334,932
336,891
320,631
317,101
317,101320,631336,891334,932343,442345,557352,856356,045368,573367,511392,519396,394288,317304,938319,242341,064340,064346,376373,148320,426324,883323,323341,263331,467885,769326,486590,800000
   > Total Current Liabilities 
0
0
0
22,800
63,251
74,862
73,377
78,313
77,950
93,422
100,832
105,197
106,768
116,648
122,382
113,807
115,066
111,468
104,018
109,788
90,101
95,335
93,298
88,015
82,952
88,126
87,627
98,053
87,809
92,141
92,14187,80998,05387,62788,12682,95288,01593,29895,33590,101109,788104,018111,468115,066113,807122,382116,648106,768105,197100,83293,42277,95078,31373,37774,86263,25122,800000
       Short-term Debt 
0
0
0
0
0
0
0
0
3,004
6,458
7,938
3,529
8,616
9,666
10,216
5,055
17,090
17,230
17,056
9,230
9,287
18,690
12,676
18,768
9,594
19,612
10,021
10,239
10,462
9,957
9,95710,46210,23910,02119,6129,59418,76812,67618,6909,2879,23017,05617,23017,0905,05510,2169,6668,6163,5297,9386,4583,00400000000
       Accounts payable 
0
0
0
1,793
3,266
2,944
2,421
4,453
3,895
3,686
5,412
3,237
5,197
6,093
8,252
3,307
5,959
2,720
4,163
8,084
6,333
9,163
4,483
7,719
12,170
9,867
7,351
7,265
6,362
6,908
6,9086,3627,2657,3519,86712,1707,7194,4839,1636,3338,0844,1632,7205,9593,3078,2526,0935,1973,2375,4123,6863,8954,4532,4212,9443,2661,793000
       Other Current Liabilities 
0
0
0
21,007
7,961
10,724
9,687
12,866
6,479
7,579
9,290
23,345
14,607
17,336
23,960
24,594
8,513
10,604
14,907
28,165
14,161
9,565
20,799
12,839
14,318
6,422
18,399
34,923
26,642
19,975
19,97526,64234,92318,3996,42214,31812,83920,7999,56514,16128,16514,90710,6048,51324,59423,96017,33614,60723,3459,2907,5796,47912,8669,68710,7247,96121,007000
   > Long-term Liabilities 
0
0
0
568,000
263,235
810,907
258,090
262,950
245,373
231,461
219,594
267,951
239,608
223,416
218,682
205,435
189,872
176,849
292,376
282,731
277,410
273,238
262,747
264,841
262,605
255,316
247,305
238,838
232,822
224,960
224,960232,822238,838247,305255,316262,605264,841262,747273,238277,410282,731292,376176,849189,872205,435218,682223,416239,608267,951219,594231,461245,373262,950258,090810,907263,235568,000000
       Long term Debt Total 
0
0
0
0
353
2,602
23,449
36,607
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000036,60723,4492,6023530000
       Other Liabilities 
0
0
0
0
263,235
246,374
234,641
226,343
208,828
188,958
177,228
163,618
144,356
119,642
110,638
98,750
84,894
74,122
191,855
183,959
180,916
0
0
0
0
0
0
0
0
0
000000000180,916183,959191,85574,12284,89498,750110,638119,642144,356163,618177,228188,958208,828226,343234,641246,374263,2350000
       Deferred Long Term Liability 
0
0
0
0
0
4,800
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000004,80000000
> Total Stockholder Equity
337,059
0
0
-258,112
288,098
-284,374
585,925
571,039
551,563
529,939
775,047
743,266
725,588
693,181
651,509
603,992
553,205
518,304
487,840
464,165
424,020
396,036
361,732
308,399
274,913
241,603
223,773
202,709
190,423
179,717
179,717190,423202,709223,773241,603274,913308,399361,732396,036424,020464,165487,840518,304553,205603,992651,509693,181725,588743,266775,047529,939551,563571,039585,925-284,374288,098-258,11200337,059
   Common Stock
0
0
0
1
11
1
12
12
12
12
13
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
15
15
1515141414141414141414141414141414141413121212121111000
   Retained Earnings -1,359,290-1,333,676-1,303,824-1,270,132-1,238,061-1,191,839-1,144,332-1,074,891-1,024,591-976,781-919,082-878,954-833,673-781,627-718,891-657,458-601,555-552,254-511,612-467,042-430,323-396,788-365,478-344,867-330,917-314,548-295,908000
   Capital Surplus 
0
0
0
0
40,981
46,160
930,208
935,834
945,026
0
0
1,253,971
1,277,197
1,294,506
1,308,946
1,324,006
1,339,601
1,357,763
1,372,751
1,387,349
1,402,692
0
0
0
0
0
0
0
0
0
0000000001,402,6921,387,3491,372,7511,357,7631,339,6011,324,0061,308,9461,294,5061,277,1971,253,97100945,026935,834930,20846,16040,9810000
   Treasury Stock000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
-561,194
602,543
46,160
930,208
935,834
945,026
958,097
1,240,649
1,253,971
1,277,197
1,294,506
1,308,946
1,324,006
1,339,601
1,357,763
1,372,751
1,387,349
1,402,692
1,421,506
1,436,859
1,452,502
1,466,844
1,479,832
1,493,891
1,506,353
1,524,084
1,538,919
1,538,9191,524,0841,506,3531,493,8911,479,8321,466,8441,452,5021,436,8591,421,5061,402,6921,387,3491,372,7511,357,7631,339,6011,324,0061,308,9461,294,5061,277,1971,253,9711,240,649958,097945,026935,834930,20846,160602,543-561,194000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue178,957
Cost of Revenue-72,080
Gross Profit106,877106,877
 
Operating Income (+$)
Gross Profit106,877
Operating Expense-269,426
Operating Income-162,549-162,549
 
Operating Expense (+$)
Research Development102,953
Selling General Administrative72,806
Selling And Marketing Expenses84,759
Operating Expense269,426260,518
 
Net Interest Income (+$)
Interest Income14,534
Interest Expense-11,580
Other Finance Cost-0
Net Interest Income2,954
 
Pretax Income (+$)
Operating Income-162,549
Net Interest Income2,954
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-159,595-165,503
EBIT - interestExpense = -159,595
-159,492
-147,912
Interest Expense11,580
Earnings Before Interest and Taxes (EBIT)-148,015-148,015
Earnings Before Interest and Taxes (EBITDA)-128,759
 
After tax Income (+$)
Income Before Tax-159,595
Tax Provision-0
Net Income From Continuing Ops-159,595-159,595
Net Income-159,492
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses341,506
Total Other Income/Expenses Net2,954-2,954
 

Technical Analysis of Adaptive Biotechnologies Corp
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Adaptive Biotechnologies Corp. The general trend of Adaptive Biotechnologies Corp is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Adaptive Biotechnologies Corp's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Adaptive Biotechnologies Corp Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Adaptive Biotechnologies Corp.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: .

The bearish price targets are: 11.92 > 11.18 > 9.9551.

Know someone who trades $ADPT? Share this with them.πŸ‘‡

Adaptive Biotechnologies Corp Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Adaptive Biotechnologies Corp. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Adaptive Biotechnologies Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Adaptive Biotechnologies Corp. The current macd is 0.26339108.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Adaptive Biotechnologies Corp price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Adaptive Biotechnologies Corp. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Adaptive Biotechnologies Corp price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Adaptive Biotechnologies Corp Daily Moving Average Convergence/Divergence (MACD) ChartAdaptive Biotechnologies Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Adaptive Biotechnologies Corp. The current adx is 34.19.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Adaptive Biotechnologies Corp shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Adaptive Biotechnologies Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Adaptive Biotechnologies Corp. The current sar is 12.37.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Adaptive Biotechnologies Corp Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Adaptive Biotechnologies Corp. The current rsi is 55.90. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Adaptive Biotechnologies Corp Daily Relative Strength Index (RSI) ChartAdaptive Biotechnologies Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Adaptive Biotechnologies Corp. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Adaptive Biotechnologies Corp price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Adaptive Biotechnologies Corp Daily Stochastic Oscillator ChartAdaptive Biotechnologies Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Adaptive Biotechnologies Corp. The current cci is 34.33.

Adaptive Biotechnologies Corp Daily Commodity Channel Index (CCI) ChartAdaptive Biotechnologies Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Adaptive Biotechnologies Corp. The current cmo is 10.35.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Adaptive Biotechnologies Corp Daily Chande Momentum Oscillator (CMO) ChartAdaptive Biotechnologies Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Adaptive Biotechnologies Corp. The current willr is -44.7761194.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Adaptive Biotechnologies Corp is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Adaptive Biotechnologies Corp Daily Williams %R ChartAdaptive Biotechnologies Corp Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Adaptive Biotechnologies Corp.

Adaptive Biotechnologies Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Adaptive Biotechnologies Corp. The current atr is 0.66454821.

Adaptive Biotechnologies Corp Daily Average True Range (ATR) ChartAdaptive Biotechnologies Corp Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Adaptive Biotechnologies Corp. The current obv is 35,493,590.

Adaptive Biotechnologies Corp Daily On-Balance Volume (OBV) ChartAdaptive Biotechnologies Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Adaptive Biotechnologies Corp. The current mfi is 44.69.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Adaptive Biotechnologies Corp Daily Money Flow Index (MFI) ChartAdaptive Biotechnologies Corp Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Adaptive Biotechnologies Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-06-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-26MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-08-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-08-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-09-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Adaptive Biotechnologies Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Adaptive Biotechnologies Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.898
Ma 20Greater thanMa 5012.807
Ma 50Greater thanMa 10011.941
Ma 100Greater thanMa 20010.807
OpenGreater thanClose12.620
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Adaptive Biotechnologies Corp with someone you think should read this too:
  • Are you bullish or bearish on Adaptive Biotechnologies Corp? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Adaptive Biotechnologies Corp? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Adaptive Biotechnologies Corp

I send you an email if I find something interesting about Adaptive Biotechnologies Corp.


Comments

How you think about this?

Leave a comment

Stay informed about Adaptive Biotechnologies Corp.

Receive notifications about Adaptive Biotechnologies Corp in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.